Cipla Introduces Needle-Free Insulin Afrezza for Diabetes Patients in India

Cipla has received approval from the Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation powder in India. Developed by MannKind Corporation in the USA, Afrezza is a groundbreaking, non-injectable insulin designed for adults with diabetes mellitus.

How Afrezza Works

Afrezza is a rapid-acting insulin delivered through an inhaler, offering a needle-free alternative to traditional insulin injections. Taken at the start of a meal, it dissolves quickly upon inhalation and enters the bloodstream within 12 minutes, mimicking the body’s natural insulin response. The drug’s effects last 2-3 hours, making it an effective solution to control post-meal sugar spikes.

Benefits for Patients

This innovative treatment is the first non-injectable insulin available for managing both type 1 and type 2 diabetes. By eliminating the need for multiple daily injections, Afrezza provides a more comfortable and convenient option, particularly for patients who are needle-averse.

Cipla’s Vision

Cipla aims to make Afrezza widely accessible, empowering millions of diabetes patients in India to manage their condition more effectively. 

About Cipla Limited

Cipla Limited, an Indian multinational pharmaceutical company based in Mumbai, specialises in creating medications for a range of health conditions, including respiratory and cardiovascular diseases, arthritis, diabetes, depression, and pediatric ailments.

As of December 12, 2024, at 9:49 AM IST, Cipla share price is ₹1,453.95, reflecting a marginal drop of ₹0.15 (0.010%) from the previous trading session. The stock opened at ₹1,460.00, reached an intraday high of ₹1,461.35, and a low of ₹1,451.95. Over the past 52 weeks, Cipla’s stock has traded between a high of ₹1,702.05 and a low of ₹1,192.10.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.